Top Gainers: Hovnanian Enterprises (NYSE:HOV), Scorpio Tankers (NYSE:STNG), CBS Corporation (NYSE:CBS), Apollo Education Group Inc (NASDAQ:APOL), Monsanto Company (NYSE:MON)

Hovnanian Enterprises, Inc. (NYSE:HOV) New Jersey’s largest homebuilder, is optimistic that demand will continue to rise though sales have been uneven in recent months. “While the housing market has improved dramatically overall compared to where it was a couple of years ago, the recent recovery has been a little more choppy,” Chief Executive Officer Ara…

Read More

Biotech New Highs: Celgene Corporation (NASDAQ:CELG), Omeros Corporation (NASDAQ:OMER), Repligen Corporation (NASDAQ:RGEN), Pain Therapeutics, Inc. (NASDAQ:PTIE)

Celgene Corporation (NASDAQ:CELG)’s stock had its “outperform” rating restated by Credit Suisse in a research note issued on Thursday. They currently have a $225.00 price target on the stock, up from their previous price target of $210.00. Credit Suisse’s target price would suggest a potential upside of 31.23% from the company’s current price. Celgene Corporation…

Read More

Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an…

Read More

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at…

Read More

Basic Material Losers: Oxford Resource Partners (NYSE:OXF), Mines Management (NYSEMKT:MGN), USEC (NYSE:USU), Alexco Resource (NYSEMKT:AXU), New Concept Energy (NYSEMKT:GBR)

Oxford Resource Partners, LP (NYSE:OXF) expected to produce between 5.7 mln tons and 6.0 mln tons for FY 2014.Expects FY 2014 adjusted EBITDA to be in range of $40 mln to $45 mln.FY 2014 EBITDA of $46 mln. Oxford Resource Partners, LP (NYSE:OXF) stock performance was -7.00% in last session and finished the day at…

Read More